Attached files
file | filename |
---|---|
8-K - CURRENT REPORT - ChromaDex Corp. | cdxc8k_sep182018.htm |
Exhibit 99.1
ChromaDex and Dartmouth College File Patent Infringement Lawsuit
Against Elysium Health
IRVINE, Calif., Sept. 18, 2018 – ChromaDex Corp. (NASDAQ:CDXC), an integrated,
science-based, nutraceutical company devoted to improving the way
people age with its flagship ingredient NIAGEN® and consumer product TRU
NIAGEN®, announced today that ChromaDex, Inc. and Trustees
of Dartmouth College filed a patent infringement complaint in the
United States District Court for the District of Delaware against
Elysium Health, Inc. (“Elysium”). The complaint alleges
that Elysium’s BASIS® dietary supplement violates
patents that cover compositions containing isolated nicotinamide
riboside (“NR”) held by Dartmouth and licensed
exclusively to ChromaDex.
Dr. Charles Brenner discovered that nicotinamide riboside (NR)
could increase levels of a vital cellular resource, oxidized
nicotinamide adenine dinucleotide (NAD+) in humans and was awarded
United States patents for his discoveries. ChromaDex is the
exclusive licensee to commercialize these patents. The
commercialized name of NR is NIAGEN.
“Elysium, a former customer of ChromaDex for NIAGEN®,
has, since 2017, been selling BASIS® dietary supplement, that
we believe infringes on the patents,” says ChromaDex CEO Rob
Fried. “We have confidence in the validity of the licensed
patents and in the strength of our intellectual property. As an
ethical company, the sales of our safety-reviewed product, TRU
NIAGEN® dietary supplement, support the inventor and the
academic institution that made this breakthrough
possible.”
About ChromaDex:
ChromaDex Corp. is an integrated, global nutraceutical
company devoted to improving the way people
age. ChromaDex scientists partner with leading
universities and research institutions worldwide to uncover the
full potential of NAD+ and identify and develop novel,
science-based ingredients. Its flagship
ingredient, NIAGEN® nicotinamide
riboside, sold directly to consumers as TRU
NIAGEN®,
is backed with clinical and scientific research, as well as
extensive IP protection. TRU NIAGEN® is helping the world AGE
BETTER®. ChromaDex
maintains a website at www.ChromaDex.com to
which ChromaDex regularly posts copies of its press releases as
well as additional and financial information about the
Company.
Important Note on Forward Looking Statements:
This
release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities and Exchange Act of 1934, as amended. Because
such statements are subject to risks and uncertainties, actual
results may differ materially from those expressed or implied by
such forward-looking statements. Such statements include statements
related to whether Elysium has infringed on ChromaDex’s
licensed patents. Other risks that contribute to the uncertain
nature of the forward-looking statements are reported in our most
recent Forms 10-Q and 10-K as filed with the SEC. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof, and actual
results may differ materially from those suggested by these
forward-looking statements. All forward-looking statements are
qualified in their entirety by this cautionary statement
and ChromaDex undertakes no obligation to revise or
update this release to reflect events or circumstances after the
date hereof.
ChromaDex Investor Relations Contact:
Andrew
Johnson, Director of Investor Relations
949-419-0288
andrewj@chromadex.com
ChromaDex Media Contact:
Alex
Worsham, Director of Strategic Partnerships
949-648-3775
alexw@chromadex.com